Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease

Background: The real-world EN-SEMBLE (jRCT1030220506) study investigated the effectiveness and safety of treatments subsequent to trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). This post hoc analysis provides i...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Junji Tsurutani, Kazuki Nozawa, Toru Mukohara, Tetsuhiko Taira, Akiyo Yoshimura, Shigenori E. Nagai, Jun Hashimoto, Kazuo Matsuura, Toshiro Mizuno, Yoshiaki Shinden, Mitsugu Yamamoto, Toshimi Takano, Makoto Wakahara, Hirofumi Terakawa, Takashi Yamanaka, Yasuyuki Kojima, Takahiro Nakayama, Yuji Hirakawa, Kazuhito Shiosakai, Hiroji Iwata
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2026-04-01
Cyfres:	Breast
Pynciau:	Interstitial lung disease Metastatic breast cancer Trastuzumab deruxtecan Subsequent treatment
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S0960977626000329
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!